The global Insulin Resistance Improvement Drug Market, according to Future Market Insights, is entering a strong growth phase, driven by the rising prevalence of obesity, type 2 diabetes, and metabolic syndrome, along with increasing adoption of advanced insulin-sensitizing therapies. The market is projected to grow from USD 10.3 billion in 2026 to USD 23.1 billion by 2036, registering a CAGR...